• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

6.900 -0.410 (-5.61%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,732,121
Open 7.170
Bid (Size) 6.980 (200)
Ask (Size) 7.020 (2,000)
Prev. Close 7.310
Today's Range 6.775 - 7.400
52wk Range 2.080 - 15.37
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 20, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
November 17, 2026
From Pomerantz LLP
Via GlobeNewswire

Performance

52-Week Range 55.1% below 52-week high
6.900
2.0852W Low 15.3752W High
1 Week 12.0% below 1-week high
6.771W Low 7.841W High

Iovance Biotherapeutics, Inc. - Common Stock (IOVA) traded between $2.08 and $15.37 over the past 52 weeks and last traded at $6.90, 55.1% below its 52-week high. Over the past week it ranged between $6.77 and $7.84.

Past 12 Months
-8.6%
-51.2%
-14.4%
+68.3%
+173.8%
+208.0%
1W -$0.65
1M -$7.24
3M -$1.16
6M +$2.80
YTD +$4.38
1Y +$4.66

IOVA was +208.0% over the past year, +68.3% over six months, +173.8% year to date, -8.6% in the last week.

12 Months vs Market
IOVA
+208.0%
DIA
+4.0%
SPY
+4.7%
QQQ
+3.1%
IWM
+8.9%

Over the past 12 months IOVA returned +208.0% versus DIA (Dow) +4.0%, SPY (S&P 500) +4.7%, QQQ (Nasdaq 100) +3.1% and IWM (Russell 2000) +8.9%.

Volume & Liquidity 0.92× 3-mo avg
Today 13,732,121 3-mo avg 14.9M
1W
9.3M
1M
14.7M
3M
14.9M
6M
15.9M
YTD
15.6M
1Y
15.1M

IOVA most recently traded 13,732,121 shares against a 3-month average daily volume of 14.9M.

More News

Read More
News headline image
Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb ↗
November 16, 2026
Via MarketBeat
News headline image
Iovance Biotherapeutics to Present at Upcoming Conference
November 12, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
IOVA SHAREHOLDER INVESTIGATION: Levi & Korsinsky Notifies Investors of Potential Securities Claims Involving Iovance Biotherapeutics, Inc. (IOVA)
November 12, 2026
From Levi & Korsinsky, LLP
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
November 10, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Iovance (IOVA) Q3 2026 Earnings Call Transcript ↗
November 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
Iovance Biotherapeutics Q3 Earnings Call Highlights ↗
November 05, 2026
Via MarketBeat
Topics Earnings
News headline image
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
November 05, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
US Stock Market Movers: Top Gainers and Losers for the Session ↗
October 29, 2026
Via Chartmill
News headline image
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Away ↗
October 29, 2026
Via The Motley Fool
Top US Stock Gainers and Losers for Oct. 29, 2026 ↗
October 29, 2026
Via Chartmill
News headline image
Iovance’s Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing ↗
October 29, 2026
Via MarketBeat
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Session ↗
October 29, 2026
Via Chartmill
Premarket Gainers and Losers on Oct. 29, 2026 ↗
October 29, 2026
Via Chartmill
News headline image
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
October 29, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
October 28, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
October 27, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
October 26, 2026
Via FinancialNewsMedia
News headline image
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
October 26, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
October 23, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
October 19, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 16, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
October 01, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗
September 29, 2026
Via Chartmill

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 6.900
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 2.11B
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap